1. Wingerchuk DM. Neuromyelitis optica. Int MS J. 2006;13:42-50. [PubMed]
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-815. [PubMed]
3. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107-1114. [PubMed]
4. O’Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996;60:382-387. [PubMed]
5. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003;60:848-853. [PubMed]
6. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106-2112. [PubMed]
7. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125:1450-1461. [PubMed]
8. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treatment Options Neurology. 2008;10:55-66. [PubMed]
9. Chan AY, Liu DT. Devic’s syndrome in systemic lupus erythematosus and probable antiphospholipid syndrome. Rheumatology. 2006;45:120-121. [PubMed]
10. Yamamoto T, Ito S, Hattori T. Neurological picture. Acute longitudinal myelitis as the initial manifestation of Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 2006;77:780. [PubMed]
11. Steinfeld S, Cogan E, King LS, Agre P, Kiss R, Delporte C. Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren’s syndrome patients. Lab Invest. 2001;81:143-148. [PubMed]
12. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of demyelination: predictors of response. Neurology. 2001;58:143-146. [PubMed]
13. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007;13:128-132. [PubMed]
14. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-477. [PubMed]
15. Saikali P, Cayrol R, Vincent T. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev. 2009;9: 132-135. [PubMed]
16. Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008;205:2473-2481. [PubMed]
17. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol. 1993;34:162-168. [PubMed]
18. de Seze J, Stojkovic T, Ferriby D, et al. Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci. 2002;197:57-61. [PubMed]
19. Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry. 1995;58:300-306. [PubMed]
20. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994;57:897-902. [PubMed]
21. de Seze J, Lebrun C, Stojkovic T, et al. Is Devic’s neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler. 2003 ;9:521-525. [PubMed]
22. Mirsattari SM, Johnston JB, McKenna R, et al. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology. 2001;56:317-323. [PubMed]
23. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66: 1485-1489. [PubMed]
24. Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology. 2004;62:226-233. [PubMed]
25. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J. 2008;15:99-105. [PubMed]
26. Poppe AY, Lapierre Y, Mélançon D, et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler. 2005;11 617-621. [PubMed]
27. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390-396. [PubMed]
28. Bonnan M, Valentino R, Olindo S, Mehdaoui H. Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009;15:487-492. [PubMed]
29. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology. 2004;63:1081-1083. [PubMed]
30. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66:1128-1133. [PubMed]
